Medication-Use Evaluation of Caspofungin In intensive Care Units of Alzahra Hospital, Isfahan, Iran, in Year 2015

Document Type : Original Article (s)

Authors

1 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Anesthesiology, School of Medicine AND Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Medication-use evaluation (MUEs) is analyzing the drug usage pattern in a treatment center and comparing it to the standards. Therefore, medication-use evaluation studies are considered to be effective and useful. Caspofungin is the first of a new class of antifungals, the echinocandins. It is used for treatment of resistant fungal infections like invasive aspergillosis, candidiasis, and empiric antifungal therapy in neutropenic fever. This study aimed to assess the pattern of the consumption of caspofungin in patients hospitalized in an intensive care unit in Isfahan, Iran in 2015, and to compare the results with the standard amounts in literature.Methods: This was a descriptive and cross-sectional (retrospective) study conducted in Alzahra hospital, Isfahan, Iran, based on the files of the patients hospitalized in the intensive care units in a six-month period in year 2015. 49 patients hospitalized in the intensive care units in this time period, had received caspofungin. The information was gathered by reviewing the patients’ medical records. Due to the specific objectives of the study, the extracted information was compared to the defined standards to be presented as percentages.Findings: The most frequent uses of this drug was for treatment of pneumonia (38.8%), sepsis (32.7%), peritonitis (20.4%), and fever and neutropenia (1.8%). The duration of treatment differed from 1 to 56 days. The administered dose of the drug was similar to the model in 92% of the cases. Decreased hemoglobin and hematocrit were the most frequent recorded drug side effects (73.4%).Conclusion: The cases of drug administration was similar to the standard model; but the dosage had a considerable difference, and the duration of use was significantly longer than the standard model.

Keywords


  1. Phillips MS, Gayman JE, Todd MW. ASHP guidelines on medication-use evaluation. American Society of Health-system Pharmacists. Am J Health Syst Pharm 1996; 53(16): 1953-5.
  2. Lewis RE. Pharmacology of echinocandins. UpTodate [Online]. [cited 2017 Sep 29]; Available from: URL: https://www.uptodate.com/contents/pharmacology-of-echinocandins?source=search_result&search=echinocandins&selectedTitle=1~56%5D
  3. Trible BR, Ramirez A, Suddith A, Fuller A, Kerrigan M, Hesse R, et al. Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition. Vaccine 2012; 30(27): 4079-85.
  4. Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. Pharmacotherapy 2004; 24(11): 1491-8.
  5. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA. Improving vancomycin prescription in critical illness through a drug use evaluation process: A weight-based dosing intervention study. Int J Antimicrob Agents 2012; 39(1): 69-72.
  6. Duke Antimicrobial Stewardship Outreach Network (DASON). Antimicrobial medication use evaluations (MUE) for community hospitals. Antimicrobial Stewardship News 2015; 3(7): 1-4.
  7. Fahimi F, Soleymani F, Tavakoli-Ardakani M. Vancomycin Utilization Evaluation in a teaching hospital: A case- series study in Iran. Journal of Pharmaceutical Care 2013; 1(2): 51-4.
  8. Hayatshahi A, Javadi M, Torkamandi H, Hadjibabaie M, Alahyari S, Gholami K, et al. Drug utilization review of vancomycin in febrhadjibabaie mile neutropenic patients hospitalized at a bone marrow transplantation center. Int J Hematol Oncol Stem Cell Res 2010; 4(3): 10-3.
  9. Salehi H. The Most Common Bacterial Agents and Their Antibiotic Sensitivity in ICU Patients of Al-Zahra Hospital in Isfahan. J Res Med Sci 2004; 9(4): 178-81.
  10. Javadi AA, Ataei B, Khourvash F, Toghiani S, Mobasherizadeh S, Soghrati M. Prevalence Of vancomycin resistant enterococci colonization in gastrointestinal tract of hospitalized patients. Iran J Clin Infect Dis 2008; 3(3): 137-41.
  11. Denning DW, Perlin DS, Muldoon EG, Colombo AL, Chakrabarti A, Richardson MD, et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. Emerg Infect Dis 2017; 23(2): 177-83.
  12. Kubiak DW, Bryar JM, McDonnell AM, Delgado- Flores JO, Mui E, Baden LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010; 32(4): 637-48.
  13. Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). UpTodate [Online]. [cited 2017 Sep 25]; Available from: URL: https://www.uptodate.com/contents/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients
  14. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 2003; 124(6): 2244-55.
  15. eMC. CANCIDAS 50 mg (formerly Caspofungin MSD) [Online]. [cited 2016 Jul 25]; Available from: URL: https://www.medicines.org.uk/emc/medicine/12843/SPC/CANCIDAS+(formerly+Caspofungin+MSD)/#PRODUCTINFO
  16. Cai MY, Lin CX, Huang WW. Efficacy analysis of caspofungin for non-effect/intolerant to fluconazole in patients with invasive fungal infection in intensive care unit. China Pharmacy 2010; 24: 028.
  17. Lewis RE. Pharmacology of echinocandins. [Online]. [cited 2017 Sep 29]; Available from: URL: https://www.uptodate.com/contents/pharmacology-of-echinocandins?search=caspofungin%20use%20guide&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
  18. Kauffman CA. Treatment of candidemia and invasive candidiasis in adults [Online]. [cited 2017 Jul 20]; Available from: URL: https://www.uptodate.com/contents/treatment-of-candidemia-and-invasive-candidiasis-in-adults?search=treatment-of-candidemia-and-invasive-candidiasisinadults&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2
  19. Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013; 32(3): 387-97.
  20. Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26(8): 723-7.
  21. FDA Advisory Committee Meeting Background. Caspofungin Acetate [Online]. [cited 2000 Dec 6]; Available from: URL: https://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf
  22. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33(9): 1529-35.
  23. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113(4): 294-9.
  24. Ratanatharathorn V, Flynn P, van Burik JA, McSweeney P, Niederwieser D, Kontoyiannis D. Micafungin in Combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients. Proceedings of the 44th Amercian Society of Hematology Annual Meeting; 2002 Dec 6-10; Philadelphia, PA, USA.